Metastatic triple negative breast cancer (TNBC) has an aggressive phenotype with a predilection for visceral.
TRIPLE NEGATIVE METASTATIC BREAST CANCER SKIN
Jaundice Itchy skin or rash Abnormally high enzymes in the liver Abdominal pain. In this Viewpoint, we offer some reasons why this may be the best explanation for the observed differences between IMpassion130 and IMpassion131. Overview of recent advances in metastatic triple negative breast cancer Abstract. Symptoms of metastasis may vary depending on where the cancer has spread to. 3, 4 We believe these discussions miss a simpler and parsimonious explanation, that atezolizumab does not improve OS in mTNBC.
Learn how its treated, and more, from MD Anderson, a top-ranked. Several explanations have been proposed for these discrepant results. Triple-negative is the most aggressive of the three most common types of breast cancer. IMpassion130 demonstrated a progression-free survival (PFS) benefit with the addition of atezolizumab to nab-paclitaxel in the intention-to-treat (ITT) analysis and PD-L1–positive subgroup and seemingly an OS benefit only in the PD-L1–positive subgroup, whereas in IMpassion131, atezolizumab plus paclitaxel did not improve PFS nor OS in the ITT or PD-L1–positive group vs paclitaxel alone. Preclinical data indicate cisplatin sensitivity, suggesting that these tumors may have defects in the BRCA1 pathway. 2 These trials tested the benefit of adding atezolizumab to taxane in first-line treatment of mTNBC. Verzenio (abemaciclib) is a treatment for both HR+, HER2-, high risk, node positive early breast cancer and for certain types of HR+, HER2- metastatic. Triple-negative breast cancer (TNBC) is characterized by lack of hormone receptors and HER-2 and shares many features with BRCA1-associated cancer.
TRIPLE NEGATIVE METASTATIC BREAST CANCER TRIAL
The results of the IMpassion131 trial that were presented at the 2020 Congress of the European Society for Medical Oncology 1 started important discussions in the oncology community about the role of atezolizumab, a programmed death–ligand 1 (PD-L1) inhibitor, in treating metastatic triple-negative breast cancer (mTNBC), especially surrounding the discrepancy in the overall survival (OS) results of the IMpassion131 trial compared with those of previously published IMpassion130.
0 kommentar(er)
